| Identification | Back Directory | [Name]
Carbamimidothioic acid, [4-[[2,3-dihydro-2,3-dioxo-5-(trifluoromethyl)-1H-indol-1-yl]methyl]phenyl]methyl ester, hydrobromide (1:1) | [CAS]
2408477-50-7 | [Synonyms]
KS106
Carbamimidothioic acid, [4-[[2,3-dihydro-2,3-dioxo-5-(trifluoromethyl)-1H-indol-1-yl]methyl]phenyl]methyl ester, hydrobromide (1:1) | [Molecular Formula]
C18H15BrF3N3O2S | [MOL File]
2408477-50-7.mol | [Molecular Weight]
474.3 |
| Hazard Information | Back Directory | [Uses]
KS106 is a potent ALDH inhibitor with IC50s of 334, 2137, 360 nM for ALDH1A1, ALDH2, and ALDH3A1, respectively. KS106 shows antiproliferative and anticancer effects with low low toxic.KS106 significantly increases ROS activity, lipid peroxidation and toxic aldehyde accumulation. KS106 induces apoptosis and cell cycle arrest at the G2/M phase[1]. | [IC 50]
ALDH2: 2137 nM (IC50); ALDH1A1: 334 nM (IC50); ALDH3A1: 360 nM (IC50) | [References]
[1] Dinavahi SS, et al. Design, synthesis characterization and biological evaluation of novel multi-isoform ALDH inhibitors as potential anticancer agents. Eur J Med Chem. 2020 Feb 1;187:111962. DOI:10.1016/j.ejmech.2019.111962 |
|
|